Balchem（BCPC）株式概要
バルケム・コーポレーションは、栄養、食品、医薬品、動物用医薬品、医療機器滅菌、植物栄養、産業市場向けの特殊機能成分および製品を開発、製造、販売している。 詳細
報酬
リスク分析
リスクチェックの結果、BCPC 、リスクは検出されなかった。
BCPC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Balchem Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$167.34 |
| 52週高値 | US$183.90 |
| 52週安値 | US$139.17 |
| ベータ | 0.81 |
| 1ヶ月の変化 | -7.69% |
| 3ヶ月変化 | 0.78% |
| 1年変化 | 8.59% |
| 3年間の変化 | 32.21% |
| 5年間の変化 | 13.73% |
| IPOからの変化 | 66,780.89% |
最新ニュース
ナラティブ更新 • Aug 18
BCPC: Share Buybacks And Index Additions Will Support Future Upside Potential
Analysts have raised their fair value estimate for Balchem from $234 to $242, linking the change to updated assumptions for revenue growth, profit margin, and future P/E that are now reflected in the latest price target reset. What’s in the News for Balchem From April 1, 2026 to June 30, 2026, Balchem repurchased 183,249 shares for US$29.64 million, representing 0.57% of shares under its ongoing buyback program.
ナラティブ更新 • Aug 04
BCPC: Record Earnings And Buybacks Will Support Strong Future Returns
Analysts have raised their price target for Balchem to $207.00 from $200.75, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Balchem Balchem reported record Q2 2026 net sales, net earnings, and adjusted EBITDA, with revenue at US$284.0 million.Seeking Alpha • Aug 02
Balchem: It's A Buy From Me After Posting Strong Q2 Results
Summary Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • Aug 18
BCPC: Share Buybacks And Index Additions Will Support Future Upside Potential
Analysts have raised their fair value estimate for Balchem from $234 to $242, linking the change to updated assumptions for revenue growth, profit margin, and future P/E that are now reflected in the latest price target reset. What’s in the News for Balchem From April 1, 2026 to June 30, 2026, Balchem repurchased 183,249 shares for US$29.64 million, representing 0.57% of shares under its ongoing buyback program.ナラティブ更新 • Aug 04
BCPC: Record Earnings And Buybacks Will Support Strong Future Returns
Analysts have raised their price target for Balchem to $207.00 from $200.75, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Balchem Balchem reported record Q2 2026 net sales, net earnings, and adjusted EBITDA, with revenue at US$284.0 million.Seeking Alpha • Aug 02
Balchem: It's A Buy From Me After Posting Strong Q2 Results
Summary Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model. Read the full article on Seeking Alphaナラティブ更新 • Jun 26
BCPC: Share Repurchases And Strong Margins Will Support Future Returns
Analysts have lifted their Balchem fair value estimate from $191 to about $200.75, citing updates to their models that include revised assumptions for revenue growth, profit margins, the discount rate, and Balchem's future P/E multiple. What’s in the News for Balchem Balchem reported that from January 1, 2026 to March 31, 2026, the company repurchased 89,880 shares, representing 0.28% of its shares, for US$14.92 million under its existing buyback program.新しいナラティブ • Mar 13
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Feb 26
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Feb 17
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.分析記事 • Feb 15
If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...ナラティブ更新 • Feb 03
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.分析記事 • Feb 01
Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...ナラティブ更新 • Jan 20
BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.ナラティブ更新 • Jan 05
BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).ナラティブ更新 • Dec 20
BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.ナラティブ更新 • Dec 06
BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.分析記事 • Dec 01
Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...分析記事 • Oct 10
Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...分析記事 • Sep 26
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Oct 28
Balchem's Q3 Shows Record Earnings And Valuation Pressure
Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
新しいナラティブ • Aug 29
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Seeking Alpha • May 10
Balchem: A Tale Of Two Businesses
Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 21
Balchem: Potential Turnaround Is In The Price
Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking Alpha株主還元
| BCPC | US Chemicals | US 市場 | |
|---|---|---|---|
| 7D | 0.3% | -1.8% | 1.8% |
| 1Y | 8.6% | 1.5% | 13.3% |
業界別リターン: BCPC過去 1 年間で1.5 % の収益を上げたUS Chemicals業界を上回りました。
リターン対市場: BCPCは、過去 1 年間で13.3 % のリターンを上げたUS市場を下回りました。
価格変動
| BCPC volatility | |
|---|---|
| BCPC Average Weekly Movement | 2.8% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
安定した株価: BCPC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BCPCの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1967 | 1,379 | Ted Harris | www.balchem.com |
バルケム・コーポレーションは、栄養、食品、医薬品、動物用医薬品、医療機器滅菌、植物栄養、産業市場向けの特殊機能性成分および製品を世界中で開発、製造、販売している。3つのセグメントで事業展開：ヒューマン・ニュートリション＆ヘルス、アニマル・ニュートリション＆ヘルス、スペシャリティ・プロダクツ。ヒューマン・ニュートリション＆ヘルス部門は、食品・飲料業界に原料を供給している。その製品には、噴霧乾燥粉末、乳化粉末、押出し・凝集、ブレンド脂質システム、液体フレーバーデリバリーシステム、ジュース・乳製品ベース、チョコレートシステム、シリアルシステム、アイスクリームベースやバリアゲートなどがある。特殊ビタミンK2、様々な用途向けのマイクロカプセル化ソリューション、栄養・健康用途向けのヒトグレードコリン栄養剤やミネラルアミノ酸キレート製品を提供している。動物栄養・健康部門は、反芻動物の健康と乳生産を向上させ、栄養補助食品を供給するためのマイクロカプセル化製品、様々な種類の畜産動物やコンパニオンアニマルに栄養吸収を高めるキレート技術、メチルスルフォニルメタン、単胃動物の健康維持のための栄養素である塩化コリンを提供しています。特殊製品部門は、主にヘルスケア産業で使用される酸化エチレンとアンモニア、再使用可能な器具を滅菌するための単回使用キャニスターを販売している。また、昆虫や微生物の腐敗を防除し、殻付き・加工ナッツ肉、加工スパイス、カカオ豆、ココアパウダー、レーズン、イチジク、プルーンなどの細菌やカビ汚染を軽減する燻蒸剤である酸化プロピレンや、高価値作物用のキレートミネラルも販売する。同社はセールスフォース、独立ディストリビューター、販売代理店を通じて製品を販売している。同社は1967年に法人化され、ニュージャージー州モントベールに本社を置いている。
Balchem Corporation 基礎のまとめ
| BCPC 基礎統計学 | |
|---|---|
| 時価総額 | US$5.33b |
| 収益（TTM） | US$164.41m |
| 売上高(TTM) | US$1.09b |
32.4x
PER（株価収益率4.9x
P/SレシオBCPC は割高か？
公正価値と評価分析を参照収益と収入
| BCPC 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.09b |
| 売上原価 | US$691.76m |
| 売上総利益 | US$394.12m |
| その他の費用 | US$229.71m |
| 収益 | US$164.41m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 5.16 |
| グロス・マージン | 36.29% |
| 純利益率 | 15.14% |
| 有利子負債／自己資本比率 | 11.7% |
BCPC の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.6%
現在の配当利回り19%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 04:52 |
| 終値 | 2026/09/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Balchem Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |